Clinical Trials
ClinicalTrials.gov is a registry and results database of publicly and privately supported clinical studies of human participants conducted around the world. Studies listed here represent active and ongoing clinical trials in the United States and Canada. Please click on the links for more information on each study including eligibility requirements and study locations. Studies listed are intended to provide a reference for trials related to rheumatologic skin disease, but the list is not comprehensive nor are the studies included specifically endorsed by RDS.
Lupus
- Comparison Between Early-onset and Late-onset Patients With Systemic Lupus Erythematosus. Mon, Oct 05, 2274
- Pharmacokinetics Study of Ianalumab in Chinese Participants With Autoimmune Diseases Sat, Oct 13, 2040
- Efficacy of Daily IV Administration of Dornase Alfa Up to 14 Days Post Subarachnoid Hemorrhage on Functional Independence At 6 Months Mon, Dec 09, 2024
- Whole Health Empowerment for Endotypes of Lupus: Improving Quality of Life in SLE Fri, Dec 06, 2024
- Assessment of Hematologic Indices in Juvenile Lupus Erythematosus Patients:Correlation With Disease Activity and Chronic Organ Damage in These Patients Thu, Dec 05, 2024
- Phase Ib/IIa Study for IPG11406 in Patients with Lupus Nephritis Thu, Dec 05, 2024
- Automated Arthritis Detection Using Artificial Intelligence on Smartphone Photographs Wed, Dec 04, 2024
- Interleukin23 in Systemic Lupus Tue, Dec 03, 2024
- Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension) Mon, Dec 02, 2024
- Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Moderate to Severe Active SLE Clinical Research Mon, Dec 02, 2024
Dermatomyositis
- Comparison Between Early-onset and Late-onset Patients With Systemic Lupus Erythematosus. Mon, Oct 05, 2274
- Pharmacokinetics Study of Ianalumab in Chinese Participants With Autoimmune Diseases Sat, Oct 13, 2040
- An Open-lable Trial of Subcutaneous Semaglutide in Systemic Scleroderma Tue, Nov 28, 2028
- MEMRI and Kidney Disease Thu, Jan 22, 2026
- Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial) Wed, Dec 17, 2025
- Efficacy of Daily IV Administration of Dornase Alfa Up to 14 Days Post Subarachnoid Hemorrhage on Functional Independence At 6 Months Mon, Dec 09, 2024
- Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial) Mon, Dec 09, 2024
- Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial) Mon, Dec 09, 2024
- Phase I/II Randomized Clinical Trial of Allogeneic Adipose Tissue-derived Mesenchymal Stromal Cells Systemic Infusion in Severe Systemic Sclerosis Mon, Dec 09, 2024
- Role of Femoral Vein Wall Thickness and Inflammatory Markers in Patients With Behcet Disease Fri, Dec 06, 2024
- Comparison Between Early-onset and Late-onset Patients With Systemic Lupus Erythematosus. Mon, Oct 05, 2274
- Pharmacokinetics Study of Ianalumab in Chinese Participants With Autoimmune Diseases Sat, Oct 13, 2040
- An Open-lable Trial of Subcutaneous Semaglutide in Systemic Scleroderma Tue, Nov 28, 2028
- MEMRI and Kidney Disease Thu, Jan 22, 2026
- Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial) Wed, Dec 17, 2025
- Efficacy of Daily IV Administration of Dornase Alfa Up to 14 Days Post Subarachnoid Hemorrhage on Functional Independence At 6 Months Mon, Dec 09, 2024
- Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial) Mon, Dec 09, 2024
- Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial) Mon, Dec 09, 2024
- Phase I/II Randomized Clinical Trial of Allogeneic Adipose Tissue-derived Mesenchymal Stromal Cells Systemic Infusion in Severe Systemic Sclerosis Mon, Dec 09, 2024
- Role of Femoral Vein Wall Thickness and Inflammatory Markers in Patients With Behcet Disease Fri, Dec 06, 2024
- Comparison Between Early-onset and Late-onset Patients With Systemic Lupus Erythematosus. Mon, Oct 05, 2274
- Pharmacokinetics Study of Ianalumab in Chinese Participants With Autoimmune Diseases Sat, Oct 13, 2040
- An Open-lable Trial of Subcutaneous Semaglutide in Systemic Scleroderma Tue, Nov 28, 2028
- MEMRI and Kidney Disease Thu, Jan 22, 2026
- Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial) Wed, Dec 17, 2025
- Efficacy of Daily IV Administration of Dornase Alfa Up to 14 Days Post Subarachnoid Hemorrhage on Functional Independence At 6 Months Mon, Dec 09, 2024
- Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial) Mon, Dec 09, 2024
- Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial) Mon, Dec 09, 2024
- Phase I/II Randomized Clinical Trial of Allogeneic Adipose Tissue-derived Mesenchymal Stromal Cells Systemic Infusion in Severe Systemic Sclerosis Mon, Dec 09, 2024
- Role of Femoral Vein Wall Thickness and Inflammatory Markers in Patients With Behcet Disease Fri, Dec 06, 2024
Systemic sclerosis
- Comparison Between Early-onset and Late-onset Patients With Systemic Lupus Erythematosus. Mon, Oct 05, 2274
- Pharmacokinetics Study of Ianalumab in Chinese Participants With Autoimmune Diseases Sat, Oct 13, 2040
- An Open-lable Trial of Subcutaneous Semaglutide in Systemic Scleroderma Tue, Nov 28, 2028
- MEMRI and Kidney Disease Thu, Jan 22, 2026
- Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial) Wed, Dec 17, 2025
- Efficacy of Daily IV Administration of Dornase Alfa Up to 14 Days Post Subarachnoid Hemorrhage on Functional Independence At 6 Months Mon, Dec 09, 2024
- Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial) Mon, Dec 09, 2024
- Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial) Mon, Dec 09, 2024
- Phase I/II Randomized Clinical Trial of Allogeneic Adipose Tissue-derived Mesenchymal Stromal Cells Systemic Infusion in Severe Systemic Sclerosis Mon, Dec 09, 2024
- Role of Femoral Vein Wall Thickness and Inflammatory Markers in Patients With Behcet Disease Fri, Dec 06, 2024
Morphea
- Comparison Between Early-onset and Late-onset Patients With Systemic Lupus Erythematosus. Mon, Oct 05, 2274
- Pharmacokinetics Study of Ianalumab in Chinese Participants With Autoimmune Diseases Sat, Oct 13, 2040
- An Open-lable Trial of Subcutaneous Semaglutide in Systemic Scleroderma Tue, Nov 28, 2028
- MEMRI and Kidney Disease Thu, Jan 22, 2026
- Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial) Wed, Dec 17, 2025
- Efficacy of Daily IV Administration of Dornase Alfa Up to 14 Days Post Subarachnoid Hemorrhage on Functional Independence At 6 Months Mon, Dec 09, 2024
- Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial) Mon, Dec 09, 2024
- Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial) Mon, Dec 09, 2024
- Phase I/II Randomized Clinical Trial of Allogeneic Adipose Tissue-derived Mesenchymal Stromal Cells Systemic Infusion in Severe Systemic Sclerosis Mon, Dec 09, 2024
- Role of Femoral Vein Wall Thickness and Inflammatory Markers in Patients With Behcet Disease Fri, Dec 06, 2024
Vasculitis
- Comparison Between Early-onset and Late-onset Patients With Systemic Lupus Erythematosus. Mon, Oct 05, 2274
- Pharmacokinetics Study of Ianalumab in Chinese Participants With Autoimmune Diseases Sat, Oct 13, 2040
- An Open-lable Trial of Subcutaneous Semaglutide in Systemic Scleroderma Tue, Nov 28, 2028
- MEMRI and Kidney Disease Thu, Jan 22, 2026
- Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial) Wed, Dec 17, 2025
- Efficacy of Daily IV Administration of Dornase Alfa Up to 14 Days Post Subarachnoid Hemorrhage on Functional Independence At 6 Months Mon, Dec 09, 2024
- Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial) Mon, Dec 09, 2024
- Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial) Mon, Dec 09, 2024
- Phase I/II Randomized Clinical Trial of Allogeneic Adipose Tissue-derived Mesenchymal Stromal Cells Systemic Infusion in Severe Systemic Sclerosis Mon, Dec 09, 2024
- Role of Femoral Vein Wall Thickness and Inflammatory Markers in Patients With Behcet Disease Fri, Dec 06, 2024
Clinical Registries
Lupus:
Cutaneous Lupus Registry at University of Pennsylvania Medical Center in Philadelphia, PA
Dermatologists at Penn established a registry for cutaneous lupus patients in 2006 to gather the large number of patients necessary for studies to better understand the development of the disease and improve our methods of diagnosis, prognosis, and treatment. The database includes a blood and tissue bank CLE Tissue Bank, which was started at Penn in 2009 as a foundation for genetic, biomarker and pathophysiologic studies.
The principal investigator for the study is Victoria Werth, MD, Professor of Dermatology at the University of Pennsylvania, an expert in the treatment of cutaneous lupus. For more information, please go to
http://www.uphs.upenn.edu/dermatology/research-clinical-trials/clinical-trials.html
Cutaneous Lupus Registry at University of Texas Southwestern Medical Center in Dallas, TX
Dermatologists at UT Southwestern have established a registry for cutaneous lupus patients and their relatives in order to gather the large number of patients necessary for studies to better understand the development of the disease and improve our methods of diagnosis, prognosis, and treatment. This registry will provide a resource for investigators to make discoveries in regards to both the clinical and molecular aspects of the disease. The principal investigator for the study is Benjamin Chong, MD, assistant professor of dermatology at UT Southwestern, director of the connective tissue diseases clinic, and an expert in the treatment of cutaneous lupus. Participants will receive newsletters detailing the progress of the registry annually. Registration of study participants, which will require an in-person evaluation and consent, is already underway. For more information, please go to
Dermatomyositis:
Dermatomyositis Patient Registry at Stanford University Medical Center in Palo Alto, CA
We are interested in enrolling patients with dermatomyositis in order to better understand the disease and help find more effective and personalized therapies. Participants are asked to donate a blood sample as well as skin biopsy. If interested, please contact one of the two participating sites:
Stanford Department of Dermatology
Principal Investigator: David Fiorentino, MD, PhD
Contact: Amanda Foster
650-421-6103
Amfoster@stanford.edu
Dermatomyositis Patient Registry at University of Pennsylvania Medical Center in Philadelphia, PA
This is a study of dermatomyositis subjects who are followed during regularly scheduled clinic visits and are asked to provide data leading to evaluation of clinical responsiveness of their skin disease. Participants can donate a blood sample as well as skin biopsy. Studies relate to effectiveness of current treatments, studies to better understand the causes of the disease, and ways to improve treatments. If interested, please contact one of the two participating sites:
University of Pennsylvania
Principal Investigator: Victoria Werth, M.D.
Contact: Joyce Okawa
Phone: 215-898-0168
http://www.uphs.upenn.edu/dermatology/research-clinical-trials/clinical-trials.html